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Prehospital treatment
of hyperkalaemia
While on placement in a large accident and emergency (A&E) department, a patient was admitted with dangerously high levels 
of potassium following immediate referral from their 
GP. Mrs Y, a 62-year-old female, displayed no signs 
of suffering an emergency medical condition. All 
observations were within normal parameters—she 
appeared systemically well and repeatedly stated 
that she felt ‘absolutely fine’. Mrs Y had a minimal 
past medical history and was normally fit and well. 
A prescription of 5 mg ramipril had been started 
several months previously because of concerns 
regarding reduced kidney function. 
Although no abnormalities were detected on 
the 3-lead or the 12-lead ECG, the patient was 
transferred to the resuscitation room with a serum 
potassium level of 7.6 mmol/L. Prompt management 
was initiated with intravenous 10% calcium 
chloride, followed by 10 units of short-acting insulin 
and 50% dextrose. 5 mg nebulized salbutamol was 
also administered. Throughout Mrs Y’s treatment, 
the ECG had been continually examined with no 
changes noted. Having been in the department for 
approximately 1 hour, Mrs Y’s serum potassium 
was stabilized at 5.1 mmol/L and the patient was 
referred to urology for further investigation and 
treatment. 
This case study is of particular interest, not 
least because of the asymptomatic presentation 
of the patient. The aggressive treatment had 
also produced near-immediate, successful 
results and the management had been relatively 
uncomplicated, with the physician following 
straightforward management advice from the 
Oxford Handbook of Emergency Care (Wyatt et 
al, 2006). Of further interest was the fact that the 
patient had been conveyed by ambulance under 
normal road conditions having not received any 
prehospital treatment.
What is hyperkalaemia?
The definition of hyperkalaemia varies from text 
to text, but is generally considered to be a plasma 
potassium concentration of greater than 5.5 mmol/L 
(Guidelines and Audit Implementation Network 
(GAIN), 2008). This can further be divided into mild 
(5.5–6 mmol/L), moderate (6.1–6.9 mmol/L) or severe 
(>7 mmol/L) (Wyatt, 2006). Potassium is the most 
abundant intracellular cation and is essential for 
physiological processes within the body, maintaining 
homeostatic cell volume and sustaining cellular 
membrane potential (Varon and Acosta, 2009). It is 
obtained through diet and is secreted predominantly 
by the kidneys but also by the gut (Irwin and Rippe, 
2008). Only 2–3% of total body potassium exists 
within extracellular fluid, translating to a normal value 
of 3.5–5.5 milliequivalents (mEq) or mmols per litre 
(LeFever Kee et al, 2009). 
Despite many studies examining the prevalence 
of hyperkalaemia in specific patient groups, the 
total number of cases is difficult to determine. 
Reports of incidence in hospitalized patients 
ranges 1–10% (GAIN, 2008) but that number can be 
somewhat larger in pre-dialyzed patients, in which 
as many as 67% develop high potassium levels 
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This article explores the assessment and management considerations of 
patients with hyperkalaemia. Using a case study from clinical practice, the 
hospital treatment is reviewed with particular emphasis upon the use of 
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Conclusions are made, including a recommendation for the prehospital use of 
salbutamol in the treatment of hyperkalaemia.
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(Khedr et al, 2009). A clear understanding of the 
emergency management is crucial as hyperkalaemia 
has lethal consequences and is associated with a 
mortality rate of 14–41% (Feld and Kaskel, 2010). 
Furthermore, severe hyperkalaemia, if not treated 
rapidly, carries a mortality rate of 67% (Weisberg, 
2008), providing a compelling argument for treating 
the condition in the prehospital phase.
Diagnosis
Signs and symptoms
To carry out appropriate management of 
hyperkalaemic patients, an understanding of the 
signs and symptoms is fundamental. An increased 
concentration of potassium in the plasma has the 
effect of depolarizing cell membranes, therefore 
making them less excitable and in turn, resulting 
in neuromuscular dysfunction (Lubin et al, 
2006). Patients with hyperkalaemia can display 
abnormal signs and symptoms specific to the renal, 
gastrointestinal, cardiovascular and nervous systems 
(LeFever Kee et al, 2009). They can present with 
nausea, abdominal pain and or/diarrhoea (Guy, 
2009); but also muscle irritability, malaise, muscle 
weakness and, in patients with serum potassium 
levels of greater than 6.0 mEq/L, paresthesia and an 
increased heart rate (LeFever Kee et al, 2009). 
Despite such an array of symptoms, it is 
commonly documented that, even with severe 
hyperkalaemia, patients can present with no 
abnormalities (Gleadle, 2007; Baltazar, 2009). This 
would explain Mrs Y’s asymptomatic presentation, 
making diagnosing the condition in the prehospital 
environment difficult, if not impossible. 
Bloods
In Mrs Y’s case, the diagnosis had been made 
on the basis of blood results and a history of 
reduced renal function—a well recognized cause 
of hyperkalaemia (Irwin and Rippe, 2008). In the 
presence of normal renal function, the attending 
doctor would suspect ‘pseudohyperkalaemia’, a 
condition in which abnormal potassium levels are 
the result of haemolysis in-vitro (Irwin and Rippe, 
2008). However, such factors are not of concern to 
UK paramedics as, despite evidence-based approval 
(Prause et al, 1997), blood gas and electrolyte 
testing is currently unavailable in the 
prehospital stage. 
The ECG
Without the help of serum potassium results 
and without the benefit of specific signs and 
symptoms, diagnosing hyperkalaemia in the 
prehospital environment could pose difficulties 
for the paramedic. However, the role of the 
electrocardiogram in recognizing the condition is 
well-documented in literature and discussed in ECG 
and medical textbooks alike (Irwin and Rippe, 2008; 
Baltazar, 2009; Jevon, 2009). ECG changes frequently 
parallel the severity of the electrolyte disorder 
(Baltazar, 2009) and, crucially, allow diagnosis of 
hyperkalaemia—giving rise to emergency treatment 
even before the results of serum potassium levels are 
available (Baltazar, 2009). 
ECG changes are varied. Potassium and sodium 
play an essential electrophysiological function 
within the myocardium, maintaining concentration 
gradients across the cell membranes with the use 
of the sodium-potassium pump. An increase in 
extracellular potassium has the effect of reducing the 
membrane potential. This in turn slows myocardial 
conduction, resulting in prolongation of the P wave, 
the PR interval and the QRS complex (Parham et 
al, 2006). These changes (Figure 1) can progress to 
ventricular fibrillation and asystole without prompt 
treatment (Barash et al, 2009), making prehospital 
management even more challenging. 
Earlier changes (Figure 3) include tall ‘peaky’ 
T waves and QT shortening (Lubin et al, 2006). The 
peaked T wave, caused by rapid repolarization, is 
best seen in leads ll, lll, and V2—V4 (Parham et al, 
2006). This draws similarities with the hyperacute 
changes of myocardial infarction, but can be 
distinguished as the T waves are relatively shorter 
in duration (<250 m sec) than those seen in 
myocardial infarction (MI) (Dananberg, 1999). 
Unfortunately, there is no widely excepted 
definition of a peaked T wave, but some have 
suggested envisaging it as a seat—if it is too 
uncomfortable to sit on, then it is likely to be 
peaked (Toy et al, 2009). 
Interestingly, despite extensive descriptions 
in the literature, recent research suggests ECG 
Figure 1. Illustration showing progressive ECG changes. 
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(Montague, 2008). This is something recognized 
by Barash et al (2009), who state that the ECG 
should provide a suggestion of hyperkalaemia but 
that the focus be upon the medical history (with 
emphasis on drug history) and assessment of renal 
function. This certainly seems a sensible approach. 
Nevertheless, Montague’s article does acknowledge 
that 80% of the patients studied had only mild or 
moderate hyperkalaemia and that the likelihood 
of ECG changes increased with rising levels of 
potassium. 
Clearly, the lack of ECG changes in the case of Mrs 
Y demonstrates that not all hyperkalaemic patients 
present with ECG changes. Indeed, the ECG is not 
sensitive enough to rule out hyperkalaemia, but 
should instead be used as an indicator for aggressive 
management where hyperkalaemic ECG changes 
exist (Wolfson et al, 2009).
Causes
Given the diagnostic abilities of the ECG, 
identifying hyperkalaemia in the prehospital 
environment is possible, enabling active 
management. Any doubt in the clinician’s mind 
could be further affirmed by recognition of an 
obvious cause of the electrolyte imbalance. 
Hyperkalaemia occurs as a result of excessive 
potassium production, cellular shifts and/
or inadequate elimination. Decreased renal 
excretion (as seen in renal failure, hyporeninemic 
hypoaldosteronism, renal tubular disease and the 
use of ACE-inhibitors and NSAIDs) is the most 
common cause of hyperkalaemia (Lee, 2009). 
This is particularly relevant to the case study, as 
Mrs Y was suffering a degree of renal dysfunction 
and had been prescribed the ACE-inhibitor 
ramipril. Other causes include potassium-sparing 
diuretics (e.g. spiralactone), tumour cell necrosis, 
metabolic acidosis and Addison’s disease (Rastergar 
and Soleimani, 2001). Of further relevance 
to the prehospital environment are burns, 
rhabdomyolysis and the use of suxamethonium (a 
paralytic drug used in rapid sequence induction), 
which can also be attributed to hyperkalaemia 
(Wilson et al, 2007). 
Management
With ECG changes indicative of hyperkalaemia and 
the presence of an obvious cause (determined by 
a thorough health history), prehospital treatment 
could be initiated. In fact, Guy (2009) advocates 
paramedic involvement in the treatment of 
hyperkalaemia, in the form of calcium gluconate, 
sodium bicarbonate, dextrose and insulin. In the 
case study, the doctor began with intravenous 10% 
calcium chloride. This should indeed be a priority, 
as calcium antagonizes the action of potassium on 
the cell membrane, reducing myocyte excitability 
and improving cardiac conduction (Sirvent 
et al, 2008). This has the effect of reversing 
electrocardiographic changes and stabilizing the 
myocardium but, notably, has no effect on lowering 
serum potassium (Hollander-Rodriquez and 
Calvert, 2006). 
It is for this reason that other, more definitive 
treatment needs to be initiated subsequently. In 
Mrs Y’s case, insulin and dextrose had been given 
concurrently. Insulin is indicated for the treatment 
of hyperkalaemia that requires emergency 
intervention and is recognized as the benchmark 
against which newer treatments are compared 
(Ahee and Crowe, 2000). 
Short-acting insulin
Short-acting insulin is administered as a firstline 
treatment. It works by stimulating the sodium/
potassium pump, an action that shifts potassium 
into the intracellular environment (Parham et al, 
2006). Studies have demonstrated insulin’s ability 
to lower potassium by 0.45 and 1.35 mEq/l (Ngugi, 
1997; Mahajan et al, 2001), with effect being 
taken within 15 minutes of administration (Allon 
and Copkney, 1990). Dextrose is administered to 
counteract the hypoglycaemic effects of insulin, 
meaning treatment should be followed by close 
monitoring of blood sugar levels (Parham et 
al, 2006). 
Despite clear evidence of insulin and dextrose’s 
success, this treatment is essentially temporary 
until removal of potassium from the body is 
Figure 2. Prolonged QRS associated with hyperkalaemia.
Figure 3. Peaked T waves associated with hyperkalaemia. 
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possible. Haemodialysis is the fastest and most 
efficient way to do this (Blumberg et al, 1988); 
but because of the time, expense and invasiveness 
involved, it is rarely used as a firstline treatment—
instead exchange resins such as sodium 
polystyrene sulfonate are preferable (Parham et al, 
2006).
Furosemide
Similarly, consideration could be given to 
furosemide—a non-potassium sparing diuretic 
and something already available to the UK 
paramedic (Joint Royal Colleges Ambulance 
Liaison Committee (JRCALC), 2006). Furosemide 
acts by preventing the tubular reabsorption of 
sodium at the loop of Henle and early distal 
tubule. This increases sodium delivery to the 
distal tubule, stimulating potassium excretion 
(Carvalhana et al, 2006). For this reason, like 
resins, it is also recommended in the removal of 
potassium in a dose of 40–80 mg (American Heart 
Association, 2005). However, the guidelines only 
suggest furosemide for the treatment of mild 
hyperkalaemia, something unlikely to be identified 
in the prehospital stage. Furthermore, a Cochrane 
review could not identify any studies that examined 
the role of loop diuretics in the treatment of high 
potassium (Mahoney et al, 2005) and, with a lack of 
a solid evidence base, it is doubtful whether there 
is any benefit to initiating this treatment in the 
prehospital phase.
Salbutamol
The same cannot be said for salbutamol. Like 
insulin, salbutamol has the effect of shifting 
potassium back into the intracellular environment. 
As a #2 agonist, it binds to #2 receptors in the 
liver and muscle cells creating a chain reaction, 
which results in stimulation of the sodium-
potassium pump (Ahee and Crowe, 2000). A 
decrease in potassium levels occurs within 1–
2 minutes, with the peak effect being reached after 
40–80 minutes (Mandelberg et al, 1999)—a faster 
effect than that of insulin. 
Salbutamol is effective in treating hyperkalaemia. 
In fact, salbutamol has been shown to be more 
effective than insulin for the treatment of 
hyperkalaemia (Mushtaq and Masood, 2006), 
reducing serum potassium levels by 0.4–1.5 mEq/
L (Mahoney et al, 2005). Results have also been 
shown to be dose dependent. Allon et al (1989) 
studied two groups of patients given 10 mg and 
20 mg salbutamol. Those receiving dosages of 
10 mg were reported as having 0.62 mmol/L 
less serum potassium, while those given 20 mg 
averaged a 0.98 mmol/L reduction. Furthermore, 
McClure et al (1994) found nebulized salbutamol 
more effective than that of the intravenous route, 
with reductions of 1.19 mmol/L and 0.7 mmol/L 
respectively. This is something supported by 
recent national guidelines (GAIN, 2008), which 
recommend 10 mg nebulized salbutamol as a 
treatment for hyperkalaemia.
The use of salbutamol has a number of 
theoretical advantages. In a best evidence topic 
report (BETs) review, Bentley (2007) summarizes 
positive features—including easy administration, 
minimal side-effects, low cost and its ability to 
reduce potassium without affecting the patient’s 
glucose balance. Moreover, salbutamol is already 
carried by all 12 UK ambulance NHS trusts and is 
well-established in prehospital clinical guidelines 
(JRCALC, 2006). Anecdotally, staff have a good 
grasp of its use in treating breathing difficulties and 
no further training would be required in the drug’s 
administration.
However, it is not without its pitfalls. Weisberg 
et al (2008) strongly state that salbutamol 
should never be used as a single treatment for 
hyperkalaemia, citing that 40% of patients seem 
resistant to its hypokalaemic effect. While this is 
something to consider, salbutamol administration 
in the prehospital setting would not act as a 
single treatment, but as an interim measure until 
definitive care could be reached and the treatment 
continued.
 Further consideration must be given to the 
adverse affects from salbutamol administration 
and prudence has been advised in patients with 
ischaemic heart disease (Ahee and Crowe, 2000), 
with cautions varying from hypertension to 
hyperthyroidism (Joint Formulary Committee, 
2010). Mild tachycardia is the most commonly 
Figure 4. Short-acting insulin is administered as a firstline 
treatment. 
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Key points
 l Hyperkalaemia is a potentially lethal condition which 
can lead to life-threatening cardiac arrhythmias and is 
associated with a high mortality rate.
 l In severe hyperkalaemia and/or the presence of 
hyperkalaemic ECG changes, urgent intervention is 
required.
 l Current in-hospital management consists of calcium 
gluconate, insulin, dextrose and salbutamol.
 l Hyperkalaemia can be diagnosed using an ECG and 
the diagnosis affirmed with signs and symptoms of 
hyperkalaemia and the presence of an obvious cause.
 l Prehospital salbutamol administration should be 
considered in patients with hyperkalaemia.
reported side-effect of high-dose salbutamol 
(Weisberg et al, 2008).
Despite such minor disadvantages, the use of 
salbutamol has been demonstrated to be safe 
and effective by a Cochrane review (Mahoney 
et al, 2005) and is accompanied by national 
clinical guidelines (GAIN, 2008) recommending 
that salbutamol be a firstline treatment for the 
management of hyperkalaemia. The guidelines 
state that in the presence of ECG changes, urgent 
treatment is required to reduce potassium.
Conclusions
Having reviewed the signs and symptoms, ECG 
changes and causes of hyperkalaemia, it seems 
there is a clear opportunity for treatment to be 
considered in the prehospital environment. Certain 
ECG changes are diagnostic in the identification 
of hyperkalaemia, giving rise to treatment in the 
absence of blood results. This diagnosis is further 
affirmed in the presence of signs and symptoms 
and an identifiable cause, most commonly renal 
dysfunction. 
Patients with ECG changes are likely to have high 
levels of potassium and are at risk of developing 
life-threatening arrhythmias within a short period 
of time. Therefore, if treatment could be initiated 
earlier, then the patient’s chance of recovery 
would perhaps be enhanced. Calcium chloride, 
insulin and salbutamol are widely discussed in the 
literature and are supported by a strong evidence 
base in the treatment of hyperkalaemia. Of these, 
only nebulized salbutamol is available to the UK 
ambulance services, a treatment which could be 
started by paramedics and technicians alike; 10 mg 
is recommended by clinical guidelines and this 
could be repeated on arrival at A&E, depending on 
the patient’s condition.
Caution should be applied in line with JRCALC’s 
guidance on salbutamol since, especially in high 
doses, side-effects may develop. Furosemide is most 
likely an inappropriate treatment for hyperkalaemia 
in the prehospital arena, but may well be used as 
part of a management plan in hospital.
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